The Lynx Group

Paul Richardson, MD


Authored Items

Letter from the Editor June 2013

Uncategorized

Progress in the treatment of hematologic malignancies has been remarkable over the past decade, primarily due to the introduction of targeted agents, a better understanding of prognostic indicators, and new data on biomarker analysis. There is no doubt that these advances have great potential for improving outcomes; however, hematologists and [ Read More ]

Sign me up!